FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson’s and Related Diseases
FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (αSyn-SAA) biomarker...
